Lessons from negative phase 3 trials in rheumatoid arthritis anno 2023-Reference-Cited by-同舟云学术

Lessons from negative phase 3 trials in rheumatoid arthritis anno 2023

Published:2023-10-30 Issue:12 Volume:82 Page:1503-1505
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Westhovens René^ORCID,Verschueren Patrick^ORCID

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference24 articles.

1. Anti-GM-CSF Otilimab versus Sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3);Taylor;Ann Rheum Dis,2023

2. Anti-GM-CSF Otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic Dmards: two phase 3 randomised trials (contRAst 1 and contRAst 2);Fleischmann;Ann Rheum Dis,2023

3. Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis

4. Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2B, dose-ranging study;Buckley;Lancet Rheumatology,2020

5. A randomized phase IIb study of mavrilimumab and golimumab in rheumatoid arthritis;Weinblatt;Arthritis Rheumatol,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial;RMD Open;2024-08